These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27378237)

  • 1. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
    Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
    Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
    Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
    Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of
    Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
    Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
    Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy.
    Chen L; Kong X; Johnston KG; Mortazavi A; Holmes TC; Tan Z; Yokomori K; Xu X
    Genome Res; 2024 Jun; 34(5):665-679. PubMed ID: 38777608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice.
    Pandey SN; Lee YC; Yokota T; Chen YW
    Mol Ther; 2014 Feb; 22(2):390-396. PubMed ID: 24232919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape.
    Beck SL; Yokota T
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
    Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
    Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
    Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
    Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
    Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J
    Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
    Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
    Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
    Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
    Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
    Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
    Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
    Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FSHD atrophic myotube phenotype is caused by DUX4 expression.
    Vanderplanck C; Ansseau E; Charron S; Stricwant N; Tassin A; Laoudj-Chenivesse D; Wilton SD; Coppée F; Belayew A
    PLoS One; 2011; 6(10):e26820. PubMed ID: 22053214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.